News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Looks to Replicate Cancer Success With Eye Drugs



8/28/2013 7:33:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Positive results for Roche's experimental eye drug should bolster its position in the multibillion-dollar-a-year market for vision loss treatments, as it looks to branch out beyond its core cancer expertise. After scrapping drugs to treat diabetes and boost levels of "good" high-density cholesterol, the world's largest maker of cancer drugs is hoping to prove it has a stronger hand when it comes to developing treatments for the eyes. The company has already chalked up one success with Lucentis, a treatment for wet age-related macula degeneration (AMD), which had sales of $1.5 billion in the United States last year.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES